{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Canakinumab+%28ACZ885%29", "query": { "intervention": "Canakinumab (ACZ885)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 68, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Canakinumab+%28ACZ885%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T18:12:55.062Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04028245", "title": "A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Spartalizumab", "type": "DRUG" }, { "name": "Canakinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 17, "start_date": "2019-08-15", "completion_date": "2026-03-05", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-09-25T18:12:55.062Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04028245" }, { "nct_id": "NCT05080218", "title": "COVID-19 VaccinE Response in Rheumatology Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis", "Psoriatic Arthritis", "Spondylarthritis" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "TNF Inhibitor", "type": "DRUG" }, { "name": "Canakinumab Injection", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Ixekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeffrey Curtis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 841, "start_date": "2021-11-15", "completion_date": "2024-05-28", "has_results": false, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-09-25T18:12:55.062Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05080218" }, { "nct_id": "NCT03447769", "title": "Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1382, "start_date": "2018-03-16", "completion_date": "2023-02-07", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-09-25T18:12:55.062Z", "location_count": 21, "location_summary": "Fayetteville, Arkansas • Los Alamitos, California • Los Angeles, California + 18 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03447769" }, { "nct_id": "NCT00798369", "title": "Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Gout" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Triamcinolone acetonide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 200, "start_date": "2008-11", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2012-04-10", "last_synced_at": "2026-09-25T18:12:55.062Z", "location_count": 27, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Buena Park, California + 23 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Buena Park", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00798369" }, { "nct_id": "NCT02007252", "title": "ACZ885 for the Treatment of Abdominal Aortic Aneurysm", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Abdominal Aortic Aneurysm (AAA)" ], "interventions": [ { "name": "ACZ885", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 65, "start_date": "2013-12", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-09-25T18:12:55.062Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02007252" }, { "nct_id": "NCT00900146", "title": "Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 556, "start_date": "2009-04", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2012-02-20", "last_synced_at": "2026-09-25T18:12:55.062Z", "location_count": 18, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Gatos", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tustin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900146" }, { "nct_id": "NCT00819585", "title": "A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gout" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Colchicine", "type": "DRUG" }, { "name": "Allopurinol", "type": "DRUG" }, { "name": "Placebo Matching Canakinumab", "type": "DRUG" }, { "name": "Placebo Matching Colchicine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 432, "start_date": "2008-12", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2018-07-17", "last_synced_at": "2026-09-25T18:12:55.062Z", "location_count": 19, "location_summary": "Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00819585" }, { "nct_id": "NCT01322321", "title": "ACZ885 in Type 1 Diabetes Mellitus", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus", "Diabetes Type 1" ], "interventions": [ { "name": "ACZ885", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "6 Years to 35 Years" }, "enrollment_count": 0, "start_date": "2011-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-09-05", "last_synced_at": "2026-09-25T18:12:55.062Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01322321" }, { "nct_id": "NCT04814368", "title": "A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Knee Osteoarthritis" ], "interventions": [ { "name": "canakinumab", "type": "BIOLOGICAL" }, { "name": "LNA043", "type": "BIOLOGICAL" }, { "name": "Placebo to canakinumab", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 23, "start_date": "2021-08-27", "completion_date": "2024-06-24", "has_results": true, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-09-25T18:12:55.062Z", "location_count": 5, "location_summary": "La Mesa, California • Clearwater, Florida • Sunrise, Florida + 2 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Sunrise", "state": "Florida" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Morehead City", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04814368" }, { "nct_id": "NCT04581343", "title": "A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pancreatic Cancer Action Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2020-11-02", "completion_date": "2023-02-27", "has_results": true, "last_update_posted_date": "2025-05-04", "last_synced_at": "2026-09-25T18:12:55.062Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04581343" } ] }